SARS-CoV-2 and SARS-CoV spike-RBD structure and receptor binding comparison and potential implications on neutralizing antibody and vaccine development
C Sun, L Chen, J Yang, C Luo, Y Zhang, J Li, J Yang… - Biorxiv, 2020 - biorxiv.org
Abstract SARS-CoV-2 and SARS-CoV share a common human receptor ACE2. Protein-
protein interaction structure modeling indicates that spike-RBD of the two viruses also has …
protein interaction structure modeling indicates that spike-RBD of the two viruses also has …
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently …
F Bertoglio, V Fühner, M Ruschig, PA Heine, L Abasi… - BioRxiv, 2020 - biorxiv.org
The novel betacoranavirus SARS-CoV-2 causes a form of severe pneumonia disease,
termed COVID-19 (coronavirus disease 2019). Recombinant human antibodies are proven …
termed COVID-19 (coronavirus disease 2019). Recombinant human antibodies are proven …
A broadly neutralizing antibody inhibits SARS-CoV-2 variants through a novel mechanism of disrupting spike trimer integrity
Y Ma, Q Mao, Y Wang, Z Zhang, J Chen, A Hao… - Cell Research, 2023 - nature.com
Dear Editor, Since the start of the COVID-19 pandemic, thousands of neutralizing antibodies
(NAbs) targeting different epitopes of the spike protein have been identified and …
(NAbs) targeting different epitopes of the spike protein have been identified and …
Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern
IA Favorskaya, DV Shcheblyakov… - Frontiers in …, 2022 - frontiersin.org
Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The
evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced …
evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced …
Protective non-neutralizing mAbs Ab94 and Ab81 retain high-affinity and potent Fc-mediated function against SARS-CoV-2 variants from Omicron to XBB1. 5
A Izadi, M Godzwon, M Ohlin, P Nordenfelt - bioRxiv, 2023 - biorxiv.org
Antibodies play a central role in the immune defense against SARS-CoV-2. There is
substantial evidence supporting that Fc-mediated effector functions of anti-spike antibodies …
substantial evidence supporting that Fc-mediated effector functions of anti-spike antibodies …
Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance
J Zou, L Li, P Zheng, W Liang, S Hu… - The Journal of …, 2022 - Am Soc Clin Investig
Many SARS-CoV-2 neutralizing antibodies (nAbs) lose potency against variants of concern.
In this study, we developed 2 strategies to produce mutation-resistant antibodies. First, a …
In this study, we developed 2 strategies to produce mutation-resistant antibodies. First, a …
[HTML][HTML] Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
Antibodies elicited in response to infection undergo somatic mutation in germinal centers
that can result in higher affinity for the cognate antigen. To determine the effects of somatic …
that can result in higher affinity for the cognate antigen. To determine the effects of somatic …
Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
H Ma, Y Guo, H Tang, CTK Tseng, L Wang, H Zong… - Cell Discovery, 2022 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs)
continue to wreak havoc across the globe. Higher transmissibility and immunologic …
continue to wreak havoc across the globe. Higher transmissibility and immunologic …
Murine monoclonal antibodies against the receptor binding domain of SARS-CoV-2 neutralize authentic wild-type SARS-CoV-2 as well as B. 1.1. 7 and B. 1.351 …
After first emerging in late 2019 in China, severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has since caused a pandemic leading to millions of infections and deaths …
(SARS-CoV-2) has since caused a pandemic leading to millions of infections and deaths …
VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
SV Kulemzin, MV Sergeeva, KO Baranov… - Journal of Personalized …, 2022 - mdpi.com
Immune evasion of SARS-CoV-2 undermines current strategies tocounteract the pandemic,
with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being …
with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being …